We revise our Revenue/EBITDA/PAT estimates for FY21/22 on the back of a healthy growth commentary and likely improvement in margins supported by market share gains. Maintain BUY with a revised TP of Rs. 3,565/share as we raise our target EV/EBITDA multiple to 12x (10x earlier)